These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 317568)

  • 1. Treatment of acute lymphoblastic leukemia with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Mitchell BS; Koller CA; Kelley WN
    Adv Exp Med Biol; 1979; 122B():347-50. PubMed ID: 317568
    [No Abstract]   [Full Text] [Related]  

  • 2. Remission induction with adenosine-deaminase inhibitor 2'-deoxycoformycin in Thy-lymphoblastic leukaemia.
    Prentice HG; Smyth JF; Ganeshaguru K; Wonke B; Bradstock KF; Janossy G; Goldstone AH; Hoffbrand AV
    Lancet; 1980 Jul; 2(8187):170-2. PubMed ID: 6105339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical pharmacology of the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Smyth JF; Paine RM; Jackman AL; Harrap KR; Chassin MM; Adamson RH; Johns DG
    Cancer Chemother Pharmacol; 1980; 5(2):93-101. PubMed ID: 6970630
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purinogenic lymphocytotoxicity: clues to a wider chemotherapeutic potential for the adenosine deaminase inhibitors.
    Kefford RF; Fox RM
    Cancer Chemother Pharmacol; 1983; 10(2):73-8. PubMed ID: 6600985
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of acute lymphoblastic leukemia with 2'-deoxycoformycin: clinical and biochemical consequences of adenosine deaminase inhibition.
    Koller CA; Mitchell BS; Grever MR; Mejias E; Malspeis L; Metz EN
    Cancer Treat Rep; 1979; 63(11-12):1949-52. PubMed ID: 316725
    [No Abstract]   [Full Text] [Related]  

  • 6. [Successful treatment with 2'-deoxycoformycin in a case of adult T-cell leukemia].
    Ishii M; Yamaguchi K; Yul LS; Oda T; Takatsuki K
    Rinsho Ketsueki; 1986 May; 27(5):780-3. PubMed ID: 3018324
    [No Abstract]   [Full Text] [Related]  

  • 7. Adenosine deaminase in malaria infection: effect of 2'-deoxycoformycin in vivo.
    Webster HK; Wiesmann WP; Pavia CS
    Adv Exp Med Biol; 1984; 165 Pt A():225-9. PubMed ID: 6609525
    [No Abstract]   [Full Text] [Related]  

  • 8. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
    Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of clinical trials of m-AMSA, dihydroxyanthracenedione, and deoxycoformycin.
    Macdonald JS; Marsoni S; Bruno S; Poster D
    Recent Results Cancer Res; 1982; 80():323-30. PubMed ID: 6977170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of adenosine deaminase to increase the antitumor activity of adenine nucleoside analogues.
    Plunkett W
    Ann N Y Acad Sci; 1985; 451():150-9. PubMed ID: 3907452
    [No Abstract]   [Full Text] [Related]  

  • 11. Relationship of 5'-nucleotidase activity and antileukemic effect in 2'-deoxycoformycin therapy.
    Wortmann RL; Holcenberg J; Poplack DG
    Cancer Treat Rep; 1982 Feb; 66(2):387-90. PubMed ID: 6275991
    [No Abstract]   [Full Text] [Related]  

  • 12. In vivo inhibition of adenosine deaminase by 2'-deoxycoformycin in mouse blood and leukemia L1210 cells.
    Agarwal RP
    Biochem Pharmacol; 1980 Feb; 29(2):187-93. PubMed ID: 6965857
    [No Abstract]   [Full Text] [Related]  

  • 13. Phenotypic conversion of acute leukaemia from T-lymphoblastic to myeloblastic induced by therapy with 2'-deoxycoformycin.
    Murphy SB; Stass S; Kalwinsky D; Rivera G
    Br J Haematol; 1983 Oct; 55(2):285-93. PubMed ID: 6604543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical consequences of adenosine deaminase inhibition in vivo. Differential effects in acute and chronic T cell leukemia.
    Mitchell BS; Sidi Y; Hershfield M; Koller CA
    Ann N Y Acad Sci; 1985; 451():129-37. PubMed ID: 3878114
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical pharmacology of deoxycoformycin.
    Major PP; Agarwal RP; Kufe DW
    Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of nucleoside transport in drug action. The adenosine deaminase inhibitor, deoxycoformycin, and the antiplatelet drugs, dipyridamole and dilazep.
    Parks RE; Dawicki DD; Agarwal KC; Chen SF; Stoeckler JD
    Ann N Y Acad Sci; 1985; 451():188-203. PubMed ID: 3878117
    [No Abstract]   [Full Text] [Related]  

  • 17. Low-dose deoxycoformycin in lymphoid malignancy.
    Grever MR; Leiby JM; Kraut EH; Wilson HE; Neidhart JA; Wall RL; Balcerzak SP
    J Clin Oncol; 1985 Sep; 3(9):1196-201. PubMed ID: 2993534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hemolysis in mice treated with deoxycoformycin, an inhibitor of adenosine deaminase.
    Smith CM; Belch A; Henderson JF
    Biochem Pharmacol; 1980 Apr; 29(8):1209-10. PubMed ID: 6966932
    [No Abstract]   [Full Text] [Related]  

  • 19. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of arabinosyladenine metabolism by 2'-deoxycoformycin in the therapy of human acute leukemia.
    Plunkett W; Nowak B; Feun LG; Benjamin RS; Keating M; Freirich EJ
    Adv Exp Med Biol; 1984; 165 Pt B():345-50. PubMed ID: 6372382
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.